DAG:lam 9/27/05 7158-71253-09 431718 S98014C

PATENT Attorney Reference Number 7158-71253-09



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re application of: Hunter et al.

Application No. 10/616,410

Filed: July 8, 2003

Confirmation No. 9290

For: NIMA INTERACTING PROTEINS

Examiner: Lei Yao, Ph.D.

Art Unit: 1642

Attorney Reference No. 7158-71253-09

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed September 27, 2005

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-referenced application are the following (collectively, an "IDS"):

☐ Information Disclosure Statement;

Form 1449, and

Copies of references (48).

Also enclosed is check no. 118084 in the amount of \$180.00 in payment of the fee prescribed by 37 C.F.R. 1.17(p). The Director is hereby authorized to charge any additional fees that may be required to file this IDS, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301

Debra A. Gordon, Ph.D. Registration No. 54,128

cc: Docketing

SEP 29 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hunter et al.

Application No. 10/616,410

Filed: July 8, 2003

Confirmation No. 9290

For: NIMA INTERACTING PROTEINS

Examiner: Lei Yao, Ph.D.

Art Unit: 1642

Attorney Reference No. 7158-71253-09

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Name: Debra on dm

Date Mailed September 27, 2005

INFORMATION DISCLOSURE STATEMENT

The above-referenced application relies upon U.S. Patent Application No. 09/275,900, filed March 24, 1999, now issued as U.S. Patent No. 6,596,848; U.S. Patent Application No. 09/066,074, filed April 24, 1998, now issued as U.S. Patent No. 5,952,467; and U.S. Patent Application No. 08/555,912, filed November 13, 1995, now issued as U.S. Patent No. 5,972,697 (collectively, "Priority Applications"), for an earlier filing date under 35 U.S.C. §120.

Listed on the accompanying form PTO-1449 are several English-language documents, some of which were disclosed to, or cited by, the United States Patent and Trademark Office ("Patent Office") in the Priority Applications. Applicants respectfully request that each document listed on the form PTO-1449 be shown as a reference cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. §1.98(a)(2)(ii)). Copies of unpublished U.S. patent applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. §1.98(a)(2)(iii) has been waived by the Patent Office (1287 OG 163). Copies of the documents listed on the accompanying form PTO-1449 that were submitted by Applicants or cited by the Patent Office in the Priority Applications need not be

09/30/2005 MAHMED1 00000001 10616410

PATENT

sent to the Patent Office (37 C.F.R. §1.98). Applicants will provide copies of any of such patents, applications, or documents upon request.

In compliance with 37 C.F.R. §1.97(c), this Information Disclosure Statement ("IDS") is being mailed before receipt of a final action, a notice of allowance, or an action that otherwise closes prosecution in the above-referenced application. Accordingly, submitted herewith is a check in the amount of \$180.00 in payment of the fee set forth in 37 C.F.R. §1.17(p). Please charge any additional fees that may be required in connection with filing this IDS, or credit any overpayment, to the deposit account referenced in the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP`

By

Debra A. Gordon, Ph.D. Registration No. 54,128

ma puden

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 228-9446

SEP 29 2005

ATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	7158-71253-09
Application Number	10/616,410
Filing Date	July 8, 2003
First Named Inventor	Hunter
Art Unit	1642
Examiner Name	Lei Yao, Ph.D.

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,443,962	08/22/1995	Draetta et al.
		5,952,467	09/14/1999	Hunter et al.
		6,596,848	07/22/2003	Hunter et al.
		2002/0025521	02/28/2002	Lu et al.
		2004/0101896	05/27/2004	Hunter et al.
		2005/0027107	02/03/2005	Hunter et al.
		2005/0049404	03/03/2005	Hunter et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 99/12962	03/1999	Lu et al.
		WIPO	WO 00/48621	08/2000	Lu et al.
		WIPO	WO 01/75067	10/2001	Drmanac et al.
		WIPO	WO 01/79449	10/2001	Tang et al.
Examiner's Initials*	Cite No. (optional)		ОТ	HER DOCUMENTS	3
		Amon et al., "Regulation of p34 ^{CDC28} tyrosine phosphorylation is not required for entry into mitosis in S. cerevisiae." Nature, 355:368-371, 1992.			

	OATE CONSIDERED:
--	---------------------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	7158-71253-09
		Application Number	10/616,410
INFORMATION DISCLOSURE STATEMENT		Filing Date	July 8, 2003
!	BY APPLICANT	First Named Inventor	Hunter
		Art Unit	1642
		Examiner Name	Lei Yao, Ph.D.
	Burgess et al., "Possible dissociation	of the heparin-binding and i	mitogenic activities of
	heparin-binding (acidic fibroblast) gr		
	site-directed mutagenesis of a single lysine residue." J. Cell Biol., 111:2129-2138, 1990.		
	Cech, "Ribozymes and Their Medica 3034, 1988.	-	, , ,
	Choi et al., "Activation of p34 ^{cdc2} protein kinase activity in meiotic and mitotic cell cycles		
	in mouse oocytes and embryos." Development, 113:789-795, 1991.		
	Chong et al., "A human telomeric protein." Science, 270:1663-1667, 1995.		
	Durfee et al., "The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit." Genes Dev., 7:555-569, 1993.		
	Dyck et al., "A Novel Macromolecular Structure Is a Target of the Promyelocyte-Retinoic		
	Acid Receptor Oncoprotein." Cell, 76:333-343, 1994.		
	Eldredge <i>et al.</i> , "Use of Tetracycline Operator System to Regulate Oncogene Expression in Mammalian Cells." <i>Methods Enzymol.</i> , 254:481-491, 1995.		
	Engleman, Human Hydbridomas and Monoclonal Antibodies, New York:Plenum Press, 1985.		
	Fields and Song, "A novel genetic system to detect protein-protein interactions." <i>Nature</i> , 340:245-246, 1989.		
	Fraley and Papahadjopoulos, "New generation lipsomes: the engineering of an efficient		
	vehicle for intracellular delivery of nucleic acids." Trends Biochem. Sci., 6:77-80, 1981.		
	Fruman <i>et al.</i> , "Immunophilins in protein folding and immunosuppression." <i>FASEB J.</i> , 8:391-400, 1994.		
	Fu and Maniatis, "Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus." <i>Nature</i> , 343:437-441, 1990.		
	Fujimori et al., "Mice Lacking Pin1 Develop Normally, but Are Defective in Entering Cell Cycle from G ₀ Arrest." Biochem. Biophys. Res. Commun., 265:658-663, 1999.		
	Gavin et al., "Histone H1 kinase acti	vity, germinal vesicle breakd	
	in mouse oocytes." J. Cell Sci., 107:	275-283, 1994.	
	Gossen and Bujard, "Tight control of responsive promoters." <i>Proc. Natl. A</i>	Acad. Sci. USA, 89:5547-555	1, 1992.
	Gui et al., "A serine kinase regulates cell cycle." Nature, 369:678-682, 19		splicing factors in the
	Hanes et al., "Sequence and Mutation Saccharomyces cerevisiae." Yeast, 5	nal Analysis of ESS1, a Gene	Essential for Growth in

EXAMINER SIGNATURE:	DATE CONSIDERED:	

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Attorney Docket Number	7158-71253-09	
	Application Number	10/616,410	
INFORMATION DISCLOSURE STATEMENT	Filing Date	July 8, 2003	
BY APPLICANT	First Named Inventor	Hunter	
	Art Unit	1642	
	Examiner Name	Lei Yao, Ph.D.	
Hani et al., "PTF1 encodes an essen shows strong homology with a new 202, 1995.	putative family of PPIases."	FEBS Lett., 365:198-	
Hannon et al., "Isolation of the Rb-r cyclins." Genes Dev., 7:2378-2391,		action with CDK2 and	
	Harper et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases." Cell, 75:805-816, 1993.		
Companion Methods Enzymol., 5:17	Heitman et al., "Identification of Immunosuppressive Drug Targets in Yeast." Methods Companion Methods Enzymol., 5:176-187, 1993.		
	Helene, "The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides." <i>Anticancer Drug Des.</i> , 6:569-584, 1991 (abstract only).		
	Hillier et al., EST-STS Database, Accession No. H41102, 1991.		
. Hillier et al., EST-STS Database, Ac	Hillier et al., EST-STS Database, Accession No. T82035, 1995.		
52-base synthetic oligonucleotide pr	Jaye et al., "Isolation of a human anti-haemophilic factor IX cDNA clone using a unique 52-base synthetic oligonucleotide probe deduced from the amino acid sequence of bovine factor IX." Nucl. Acid Res., 11(8):2325-2335, 1983.		
Jung et al., "Kinetics of MPF and hi	Jung et al., "Kinetics of MPF and histone H1 kinase activity differ during the G2- to M-phase transition in mouse oocytes." Int. J. Dev. Biol., 37:595-600, 1993.		
Kohler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity." <i>Nature</i> , 256:495-497, 1975.			
immunoreactive alpha-inhibin precu 78:433-439, 1994.	Lambert-Messerlian et al., "Human follicular fluid contains pro- and C-terminal immunoreactive alpha-inhibin precursor proteins." J. Clin. Endocrinol. Metab.,		
Lazar <i>et al.</i> , "Transforming growth to 48 results in different biological actions."			
Lee and Nathans, "Proliferin Secrete Receptors." J. Biol. Chem., 263(7):	ed by Cultured Cells Binds to 3521-3527, 1988.	Mannose 6-Phosphase	
Lu et al., "Properties and regulation Aspergillus nidulans." J. Biol. Chen	n., 268:8769-8776, 1993.	•	
Lu et al., "Identification of Substrate regulated NIMA Protein Kinase." J.	- ·	<u>-</u>	
Lu et al., "Evidence for a NIMA-lik 81:413-424, 1995.			

SIGNATURE: CONSIDERED:	EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	------------------------	---------------------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	7158-71253-09	
		Application Number	10/616,410	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	July 8, 2003	
		First Named Inventor	Hunter	
		Art Unit	1642	
		Examiner Name	Lei Yao, Ph.D.	
	Lu <i>et al.</i> , "Expression of the noncata in Aspergillus nidulans." <i>EMBO J.</i> ,		inase causes a G2 arrest	
	Lu et al., "A human peptidyl-prolyl Nature, 380:544-547, 1996	isomerase essential for regula	ation of mitosis."	
Maher et al., "Oligonucleotide-Directed DNA Triple-Helix Formation: An Approx Artificial Repressors?" Antisense Res. Dev., 1:277-281, 1991.			ation: An Approach to	
Mannino and Gould-Fogerite, "Liposome Mediated Gene Transfer." <i>Biotechniques</i> , 6(7):682-690, 1988.			· ·	
Marcus-Sekura, "Review: Techniques for Using Antisense Oligodeoxyribonucleoti Study Gene Expression." <i>Anal. Biochem.</i> , 172:289-295, 1988.			odeoxyribonucleotides to	
Morris et al., "The genetic analysis of mitosis in Aspergillus nidulans." Bioessays, 10:196-201, 1989.			ılans." <i>Bioessays</i> ,	
	O'Connell <i>et al.</i> , "Premature chromatin condensation upon accumulation of NIMA." <i>EMBO J.</i> , 13:4926-4937, 1994.			
	Osmani <i>et al.</i> , "Mitotic induction and maintenance by overexpression of a G2-specific gene that encodes a potential protein kinase." <i>Cell</i> , 53:237-244, 1988.			
Osmani et al., "Parallel Activation of the NIMA and p34 ^{cdc2} Cell Cycle-Regulated Pro Kinases Is Required to Initiate Mitosis in A. nidulans." Cell, 67:283-291, 1991. Peattie et al., "Expression and characterization of human FKBP52, an immunophilin to associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes." Proc. Natl. Acad. Sci. USA, 89:10974-10979, 1992.			•	
			t of steroid receptor	
	Rahfeld <i>et al.</i> , "Confirmation of the existence of a third family among peptidyl-proly cis/trans isomerases: Amino acid sequence and recombinant production of parvulin." FEBS Lett., 352:180-184, 1994.			
	Rosborough et al., "Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography." Transplantation Proc., 23:2890-2893, 1991.			
,	Rosenberg et al., "Vectors for select polymerase." Gene, 56:125-135, 19	87.		
	Rudd <i>et al.</i> , "A new family of peptid 20:12-14, 1995.			
	Sazer <i>et al.</i> , "Mitochondrial growth a DNA replication in fission yeast." <i>J</i>			
	Schreiber, "Chemistry and Biology of Ligands." <i>Science</i> , 251:283-287, 19	-	eir Immunosuppressive	

EXAMINER DATE CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Attorney Docket Number	7158-71253-09	
	Application Number	10/616,410	
INFORMATION DISCLOSURE STATEMENT	Filing Date	July 8, 2003	
BY APPLICANT	First Named Inventor	Hunter	
	Art Unit	1642	
	Examiner Name	Lei Yao, Ph.D.	
Schultz et al., "Cell Cycle-deper Related to the NIMA Mitotic Re 5:625-635, 1994.	ndent Expression of Nek2, a Novegulator of Asperigillus nidulans	vel Human Protein Kinase l." Cell. Growth Differ.,	
Schultz et al., "Identification of of a Family Related to the Cell (Growth Differ., 4:821-830, 1993	Cycle Regulator nimA of Aspergi		
with similarity to Aspergillus nic	Schweitzer et al., "NPK1, a nonessential protein kinase gene in Saccharomyces cerevisiae with similarity to Aspergillus nidulans nimA." Mol. Gen. Genet., 234:164-167, 1992.		
Efficient Manipulation of DNA 1989.			
phosphorylation of p34 ^{cdc28} ." No	Sorger and Murray, "S-phase feedback control in budding yeast independent of tyrosine phosphorylation of p34 ^{cdc28} ." <i>Nature</i> , 355:365-368, 1992.		
Promote Entry into Mitosis in ch	Stueland et al., "Full Activiation of p34 ^{CDC28} Histone H1 Kinase Activity Is Unable To Promote Entry into Mitosis in checkpoint-Arrested Cells of the Yeast Saccharomyces cerevisiae." Mol. Cell. Bio., 13:3744-3755, 1993.		
	Sudol et al., "Characterization of a novel protein-binding module – the WW domain."		
Sudol et al., "Characterization o Its Role in Defining a Novel Pro 270(24):14733-14741, 1995.	•	·	
Wallace et al., "The use of synth Hybridization of oligonucleotide Acid Res., 9(4):879-894, 1981.	Wallace et al., "The use of synthetic oligonucleotides as hybridization probes. II. Hybridization of oligonucleotides of mixed sequence to rabbit β -globin DNA." Nucl.		
Weintraub, "Antisence RNA and			
Yocum et al., "Use of lacZ fusion Divergent GAL1-GAL10 Promoted 4(10):1985-1998, 1984.	er in Saccharomyces cerevisiae.	" Mol. Cell. Bio.,	
Yoon et al., "Genetic and Bioch Protein, Cbf2p/Ndc10p, and the Biol., 15:4835-4842, 1995			

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.